Report : North America Pharmaceutical Excipients Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Bioresorbable Polymers, and Lipids and Liposome-Based Formulation; Oleochemicals; Sugars; Cellulose; Starches; Petrochemicals; Plant Proteins and Polyols and Cyclodextrins; Inorganic Chemicals; and Others), Clinical Indication (Cancer, Metabolic, Infectious Diseases, Dental, Ophthalmic, Gene Therapies, and Others), Functionality (Coloring Agent and Coating Agent, Sweetener and Flavoring Agents, Suspending and Viscosity Agents, Preservative and Controlled-Release, Antioxidant and Oil, Tablet Filler and Diluents, Binders and Compression Aids and Granulating Agents, and Others), Application (Parenteral, Oral Formulations and Tablets, Capsules, Liquid and Injectables, Physicochemical Excipient-Container Interactions in Prefilled Syringes, Nutraceuticals and OTC, Topical, and Others), and End User (Biopharma Industries, Pharma Industries, Animal Health, and Others)
At 6.2% CAGR, the North America Pharmaceutical Excipients Market is speculated to be worth US$ 5,326.59 million by 2028, says Business Market Insights
According to Business Market Insights’ research, the North America pharmaceutical excipients market was valued at US$ 3,715.72 million in 2022 and is expected to reach US$ 5,326.59 million by 2028, registering a CAGR of 6.2% from 2022 to 2028. Growing generics and increasing product launches are the critical factors attributed to the North America pharmaceutical excipients market expansion.
Governments of developing countries are focusing on reducing healthcare costs by boosting the production of generic drugs. In addition, many drugs are on the brink of losing their patents. Generic drug companies can produce replicas of branded drugs when patents of original drugs expire. The replicas can cost up to 80% less than the originals. Therefore, the generics industry has witnessed remarkable growth in the last decade as the patents of many branded drugs have expired, with companies achieving above-average shareholder returns. Excipients are an integral component of pharmaceutical products that determine the structure of dosage type and its role in delivering drugs. The principal role of excipients is to support patient acceptability, enhance stability, bioavailability, and assist in the effectiveness. Thus, the rise in the sale of generic drugs across the region propels the demand for pharmaceutical excipients used in manufacturing generic drugs.
On the contrary, cost and time-intensive drug development process hurdles the growth of North America pharmaceutical excipients market.
Based on type, the North America pharmaceutical excipients market is segmented into bioresorbable polymers & lipids & liposome-based formulation, oleochemicals, sugars, cellulose, starches, petrochemicals, plant protein & polyols & cyclodextrins, inorganic chemicals, and others. The inorganic chemicals segment held 29.5% market share in 2022, amassing US$ 1,094.53 million. It is projected to garner US$ 1,517.75 million by 2028 to expand at 5.6% CAGR during 2022–2028.
Based on clinical indication, the North America pharmaceutical excipients market is segmented into cancer, metabolic, infectious diseases, dental, ophthalmic, gene therapies, and others. The cancer segment held 33.7% market share in 2022, amassing US$ 1,251.10 million. It is projected to garner US$ 1,751.81 million by 2028 to expand at 5.8% CAGR during 2022–2028.
Based on functionality, the North America pharmaceutical excipients market is segmented into coloring agent & coating agents, sweetener & flavoring agents, suspending & viscosity agents, preservative & controlled-release, antioxidant & oil, tablet filler & diluents, binders & compression aids & granulating agents, emulsifiers, and others. The tablet filler and diluents segment held 24.2% market share in 2022, amassing US$ 900.88 million. It is projected to garner US$ 1,365.19 million by 2028 to expand at 7.2% CAGR during 2022–2028.
Based on application, the North America pharmaceutical excipients market is segmented into parenteral, orals formulations & tablets, capsules, liquid & injectable, physicochemical excipient container interactions in prefilled syringes, nutraceuticals & OTC, topical, and others. The orals formulations & tablets segment held 41.0% market share in 2022, amassing US$ 1,524.38 million. It is projected to garner US$ 2,258.99 million by 2028 to expand at 6.8% CAGR during 2022–2028.
Based on end user, the North America pharmaceutical excipients market is segmented into biopharma industries, pharma industries, animal health, and others. The pharma industries segment held 45.0% market share in 2022, amassing US$ 1,673.15 million. It is projected to garner US$ 2,369.65 million by 2028 to expand at 6.0% CAGR during 2022–2028.
Based on country, the North America pharmaceutical excipients market is segmented into the US, Canada, and Mexico. Our regional analysis states that the US captured 84.8% market share in 2022. It was assessed at US$ 3,149.81 million in 2022 and is likely to hit US$ 4,480.20 million by 2028, exhibiting a CAGR of 6.0% during the forecast period.
Key players dominating the North America pharmaceutical excipients market are Archer-Daniels-Midland Co, AshLand Inc, Avantor Inc, BASF SE, Evonik Industries AG, JRS PHARMA GmbH & Co. KG, MEGGLE GmbH & Co KG, Roquette Freres SA, The Dow Chemical Co, and The Lubrizol Corp among others.
- In 2020, Evonik launched RESOMER Precise platform of custom functional excipients to precisely control the release profile of parenteral drug products.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com